The HAS inhibitor, 4-methylumbelliferone (4-MU)31, which does not alter the ability of CD44 to bind HA32, depletes glucuronic acid, a building block of HA synthesis and decreases expression of HAS2/3, by about 60–80% in cancer cell lines. This evidence concerns the gene CD44 and cancer.